MA-NETSCOUT-SYSTEMS
21.9.2021 12:03:07 CEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations.
In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks has been felt worldwide. As a result, leading governments are introducing new programs and policies to defend against attacks, and policing organizations are initiating unprecedented collaborative efforts to address the crisis.
During 1H2021, cybercriminals weaponized and exploited seven newer reflection/amplification DDoS attack vectors putting organizations at greater risk. This attack vector explosion spurred an increase in multivector DDoS attacks with a record-setting 31 attack vectors deployed in a single attack against one organization.
Other key findings from the NETSCOUT 1H2021 Threat Intelligence Report include:
- New adaptive DDoS attack techniques evade traditional defenses. By customizing their strategies, cybercriminals evolved their attack efforts to bypass cloud-based and on-premise static DDoS defenses to target commercial banks and credit card processors.
- Connectivity supply chain increasingly under attack. Bad actors looking to cause the most collateral damage focused their efforts on vital internet components, including DNS servers, virtual private network (VPN) concentrators, services, and internet exchanges, disrupting essential gateways.
- Cybercriminals add DDoS to their toolkit to launch triple extortion campaigns. Ransomware has become big business, with extortionists adding DDoS to their attack regimen to ratchet up the pressure on victims and add stress to security teams. Triple extortion combines file encryption, data theft, and DDoS attacks, increasing the possibility that cyber criminals receive payment.
- The fastest DDoS attack recorded a 16.17% year-over-year increase. A Brazilian wireline broadband internet user launched the attack, which was likely related to online gaming. Using DNS reflection/amplification, TCP ACK flood, TCP RST flood, and TCP SYN/ACK reflection/amplification vectors, the sophisticated attack recorded 675 Mpps.
- The largest DDoS attack, 1.5 Tbps, represented a year-over-year increase of 169%. ASERT data identified this attack against a German ISP, deploying a DNS reflection/amplification vector. This attack represents a dramatic increase in size over any attacks recorded in 1H2020.
- Botnets contribute to major DDoS activity - Tracked botnet clusters and high-density attack-source zones worldwide showcased how malicious adversaries abused these botnets to participate in more than 2.8 million DDoS attacks. In addition, well-known IoT botnets Gafgyt and Mirai continue to pose a severe threat contributing to more than half of the total number of DDoS attacks.
"Cybercriminals are making front-page news launching an unprecedented number of DDoS attacks to take advantage of the pandemic's remote work shift by undermining vital components of the connectivity supply chain," stated Richard Hummel, threat intelligence lead, NETSCOUT. "Ransomware gangs added triple-extortion DDoS tactics to their repertoire. Simultaneously, the Fancy Lazarus DDoS extortion campaign kicked into high gear threatening organizations in multiple industries with a focus on ISPs and specifically their authoritative DNS servers."
NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data secured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with NETSCOUT's ATLAS Security Engineering & Response Team (ASERT) insights.
The visibility and analysis represented in the Threat Intelligence Report and Omnis® Threat Horizon fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security product portfolio to detect and block threat activity for enterprises and service providers worldwide.
For more information on NETSCOUT's semi-annual Threat Intelligence Report, please visit our interactive website . You can also find us on Facebook , LinkedIn, and Twitter for threat updates and the latest trends and insights.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our Omnis® cybersecurity advanced threat detection and response platform offers comprehensive network visibility, threat detection, highly contextual investigation, and automated mitigation at the network edge. NETSCOUT nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.
©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005395/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
